Services and expertise in Personalized Tumor Therapy: from molecular analysis to personalized therapy

Currently, one in four deaths is caused by cancer – mainly as a result of metastatic disease spread. The focus of this project group, therefore, is on the development of diagnostic tests to enable detection of disseminated cancer cells early in the disease and prediction of the response to therapy of metastatic progenitor cells. Since the currently available therapies are effective only in one in four cancer patients, we aim to develop novel targeted systemic treatment options.

Our Project Group on Personalized Tumor Therapy is now ISO 9001 certified

The Fraunhofer ITEM Project Group on Personalized Tumor Therapy, based in Regensburg (Germany), has been certified by TÜV SÜD according to DIN ISO 9001:2015 and thus now complies with international requirements. The independent technical service corporation TÜV SÜD will perform routine inspection of structures, workflows, and processes in our project group. This provides the following benefits for ourselves and our clients:

 

Sustainable quality management
Minimization of risks
Worldwide comparability
Continued optimization of processes
Early recognition of possible improvements
Fulfillment of special customer requirements
Higher client and employee satisfaction

 

 

The quality management standard ISO 9001 is the most widely established and most relevant quality management standard, both nationally and internationally.

Contact

Christoph Andreas Klein

Contact Press / Media

Prof. Dr. med. Christoph Andreas Klein

Head of Project Group

Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM
Am BioPark 9
93053 Regensburg

Phone +49 941 298480-55

Bernhard Michael Polzer

Contact Press / Media

Dr. med. Bernhard Michael Polzer

Head of department

Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM
Am BioPark 9
93053 Regensburg

Phone +49 941 298480-23